Di-macrocyclic Chelators for Selective Thorium Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chelating agents for anticancer therapy face challenges in selectively binding thorium while avoiding depletion of essential biological metal ions, leading to potential health issues due to non-selective binding of biologically significant metals.
Innovation Solution
Development of di-macrocyclic chelators with specific chelating moieties and linkers that selectively bind thorium, utilizing oxygen donors to form stable complexes, thereby minimizing interaction with essential biological metals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current chelating agents are used for anticancer therapy, then thorium binding capability is achieved, but essential biological metal ions are depleted due to non-selective binding
Solution Approach 1:
The patent applies local quality by designing chelating agents with specific functional groups (oxygen donors from carboxylate and hydroxamate moieties) positioned in a specific spatial arrangement within the chelating cavity. This localized chemical environment creates high affinity and selectivity for thorium ions while excluding biologically essential metals, thereby achieving reliable thorium binding without depleting essential biological metals.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical composition and structural parameters of chelating agents to optimize thorium selectivity. Specific parameters including the type of oxygen donors (carboxylate vs. hydroxamate), the denticity of chelating groups, and the macrocyclic cavity size are adjusted to create chelators that preferentially bind thorium over other metal ions, thus achieving high selectivity without harmful side effects.
2Quantity of substance
If non-selective chelating agents are used, then metal ion binding is achieved, but side effects occur due to interaction with biologically significant metals
Solution Approach 1:
The patent applies segmentation by dividing the chelating agent into distinct functional modules: macrocyclic scaffolds providing structural framework, carboxylate groups for initial metal coordination, and hydroxamate groups for selective thorium binding. This segmented design allows each component to contribute specifically to thorium binding while minimizing non-specific interactions with biological metals, maintaining high binding capacity without side effects.
Solution Approach 2:
The patent uses composite materials by combining different chelating functional groups (carboxylate and hydroxamate) within a single chelating agent molecule. This composite structure creates a synergistic effect where the combination of oxygen donors provides both high metal ion binding capacity and exceptional selectivity for thorium, eliminating the need to choose between binding capacity and selectivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The di-macrocyclic chelators achieve high selectivity for thorium, reducing the depletion of essential biological metals and enhancing the therapeutic efficacy while minimizing side effects.
Implementation Method 1
Development of di-macrocyclic chelators with specific chelating moieties and linkers that selectively bind thorium, utilizing oxygen donors to form stable complexes
Data Source
AI summary
The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.